Broadcast

Visitation Alert

Back

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (Pediatric MATCH)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; El-Shami, Jessica; Leffin, Melissa

  • IRB No: APEC1621E

    Protocol Abbrev: APEC1621E

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621E

    Treatment: Other: Laboratory Biomarker Analysis; Drug: Selumetinib; Drug: Selumetinib Sulfate

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT03213691

  • Objective

    To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in the MAPK pathway.

  • Key Eligibility

    Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
    Sexes Eligible for Study: All
    Accepts Healthy Volunteers: No